Articles related to BIOLOGIC TREATMENTS

A first joint EULAR/PReS guideline unifies systemic juvenile idiopathic arthritis and adult-onset Still’s disease under a single name, Still’s disease, and recommends early IL-1 or IL-6 inhibitor therapy over prolonged glucocorticoid use.

The GINA 2026 update introduces age-stratified primary care flowcharts for asthma exacerbation management, expands biologic guidance including depemokimab, and adds a formal red-flag list for fatal or near-fatal asthma risk in adults and adolescents.

A pediatric gastroenterology expert outlines when extrapolation of adult IBD therapies to children is reasonable, where it falls short, and how shared decision-making should be structured.

A 9-member Delphi panel just issued 65 implementation recommendations for anti-amyloid mAbs in private practice. Here’s what counts as practice-shaping and what’s still consensus opinion.

To limit or even avoid the negative impact of ERA and JPsA on patient development, QoL or disease-associated joint damage, rapid and sustained control of disease signs and symptoms is recommended.

“Hidradenitis suppurativa (HS) affects far more than skin; it impacts confidence, emotional well-being and relationships during a formative period for many pediatric patients.” – Brindley Brooks, Founder & CEO, HS Connect.